{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T18:43:36Z","timestamp":1790102616087,"version":"4.0.1"},"reference-count":101,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2020,7,27]],"date-time":"2020-07-27T00:00:00Z","timestamp":1595808000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Failure of conventional treatments is often observed in cancer management and this requires the development of alternative therapeutic strategies. However, new drug development is known to be a high-failure process because of the possibility of a lower efficacy than expected for the drug or appearance of non-manageable side effects. Another way to find alternative therapeutic drugs consists in identifying new applications for drugs already approved for a particular disease: a concept named \u201cdrug repurposing\u201d. In this context, several studies demonstrated the potential anti-tumour activity exerted by \u03b11-adrenergic receptor antagonists and notably renewed interest for naftopidil as an anti-cancer drug. Naftopidil is used for benign prostatic hyperplasia management in Japan and a retrospective study brought out a reduced incidence of prostate cancer in patients that had been prescribed this drug. Further studies showed that naftopidil exerted anti-proliferative and cytotoxic effects on prostate cancer as well as several other cancer types in vitro, as well as ex vivo and in vivo. Moreover, naftopidil was demonstrated to modulate the expression of Bcl-2 family pro-apoptotic members which could be used to sensitise cancer cells to targeting therapies and to overcome resistance of cancer cells to apoptosis. For most of these anti-cancer effects, the molecular pathway is either not fully deciphered or shown to involve \u03b11-adrenergic receptor-independent pathway, suggesting off target transduction signals. In order to improve its efficacy, naftopidil analogues were designed and shown to be effective in several studies. Thereby, naftopidil appears to display anti-cancer properties on different cancer types and could be considered as a candidate for drug repurposing although its anti-cancerous activities need to be studied more deeply in prospective randomized clinical trials.<\/jats:p>","DOI":"10.3390\/ijms21155339","type":"journal-article","created":{"date-parts":[[2020,7,28]],"date-time":"2020-07-28T10:16:49Z","timestamp":1595931409000},"page":"5339","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Drug Repositioning of the \u03b11-Adrenergic Receptor Antagonist Naftopidil: A Potential New Anti-Cancer Drug?"],"prefix":"10.3390","volume":"21","author":[{"given":"Romane","family":"Florent","sequence":"first","affiliation":[{"name":"Normandie Univ, UNICAEN, INSERM U1086 ANTICIPE (Interdisciplinary Research Unit for Cancers Prevention and Treatment), BioTICLA axis (Biology and Innovative Therapeutics for Ovarian Cancers), 14000 Caen, France"},{"name":"UNICANCER, Comprehensive Cancer Center Fran\u00e7ois Baclesse, 14000 Caen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Poulain","sequence":"additional","affiliation":[{"name":"Normandie Univ, UNICAEN, INSERM U1086 ANTICIPE (Interdisciplinary Research Unit for Cancers Prevention and Treatment), BioTICLA axis (Biology and Innovative Therapeutics for Ovarian Cancers), 14000 Caen, France"},{"name":"UNICANCER, Comprehensive Cancer Center Fran\u00e7ois Baclesse, 14000 Caen, France"},{"name":"Biological Ressources Center \u00abOvaRessources\u00bb, Comprehensive Cancer Center Fran\u00e7ois Baclesse, 14000 Caen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8867-0778","authenticated-orcid":false,"given":"Monique","family":"N'Diaye","sequence":"additional","affiliation":[{"name":"Normandie Univ, UNICAEN, INSERM U1086 ANTICIPE (Interdisciplinary Research Unit for Cancers Prevention and Treatment), BioTICLA axis (Biology and Innovative Therapeutics for Ovarian Cancers), 14000 Caen, France"},{"name":"UNICANCER, Comprehensive Cancer Center Fran\u00e7ois Baclesse, 14000 Caen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,7,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1126\/science.aam7344","article-title":"PARP inhibitors: Synthetic lethality in the clinic","volume":"355","author":"Lord","year":"2017","journal-title":"Science"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/avj.12747","article-title":"Tumour angiogenesis, anti-angiogenic therapy and chemotherapeutic resistance","volume":"96","author":"Mander","year":"2018","journal-title":"Aust. Vet. J."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1172\/JCI83871","article-title":"Cancer immunotherapy: Harnessing the immune system to battle cancer","volume":"125","author":"Yang","year":"2015","journal-title":"J. Clin. Investig."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.tips.2013.06.005","article-title":"Cancer drug discovery by repurposing: Teaching new tricks to old dogs","volume":"34","author":"Gupta","year":"2013","journal-title":"Trends Pharm."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.7150\/ijbs.24612","article-title":"Review of drug repositioning approaches and resources","volume":"14","author":"Xue","year":"2018","journal-title":"Int. J. Biol. Sci."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: Progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.drudis.2018.01.018","article-title":"A bibliometric review of drug repurposing","volume":"23","author":"Baker","year":"2018","journal-title":"Drug Discov. Today"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.jsxm.2016.02.166","article-title":"Efficacy and safety of sildenafil by age in men with erectile dysfunction","volume":"13","author":"Goldstein","year":"2016","journal-title":"J. Sex. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.phrs.2017.07.013","article-title":"Drug repurposing in cancer","volume":"124","author":"Sleire","year":"2017","journal-title":"Pharm. Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.diabres.2018.05.023","article-title":"Metformin in cancer","volume":"143","author":"Mallik","year":"2018","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1042\/BJ20150497","article-title":"Repurposing metformin: An old drug with new tricks in its binding pockets","volume":"471","author":"Pryor","year":"2015","journal-title":"Biochem. J."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Sauter, E.R. (2018). Breast cancer prevention: Current approaches and future directions. Eur. J. Breast Health.","DOI":"10.5152\/ejbh.2018.3978"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.3802\/jgo.2019.30.e10","article-title":"Current state and outlook for drug repositioning anticipated in the field of ovarian cancer","volume":"30","author":"Kobayashi","year":"2019","journal-title":"J. Gynecol. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2174\/1568009615666141229152812","article-title":"Potential anti-cancer drugs commonly used for other indications","volume":"15","author":"Hanusova","year":"2015","journal-title":"Curr. Cancer Drug Targets"},{"key":"ref_15","first-page":"171","article-title":"Localization of mRNA for three distinct alpha 1-adrenergic receptor subtypes in human tissues: Implications for human alpha-adrenergic physiology","volume":"45","author":"Price","year":"1994","journal-title":"Mol. Pharm."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0014-2999(99)00222-8","article-title":"Alpha1-adrenoceptor subtypes","volume":"375","author":"Zhong","year":"1999","journal-title":"Eur. J. Pharm."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.ejphar.2019.04.047","article-title":"The pharmacology of \u03b11-adrenoceptor subtypes","volume":"855","author":"Docherty","year":"2019","journal-title":"Eur. J. Pharm."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/S0006-2952(01)00589-5","article-title":"Role of G(i)-proteins in norepinephrine-mediated vasoconstriction in rat tail artery smooth muscle","volume":"61","author":"Petitcolin","year":"2001","journal-title":"Biochem. Pharm."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1111\/j.1464-410X.2008.08086.x","article-title":"Current role of alpha-blockers in the treatment of benign prostatic hyperplasia","volume":"102","author":"Kaplan","year":"2008","journal-title":"BJU Int."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1146\/annurev-med-063014-123902","article-title":"Management of benign prostatic hyperplasia","volume":"67","author":"Kim","year":"2016","journal-title":"Annu. Rev. Med."},{"key":"ref_21","first-page":"S7","article-title":"Medical therapy for benign prostatic hyperplasia: A review","volume":"22","author":"Asseldonk","year":"2015","journal-title":"Can. J. Urol."},{"key":"ref_22","first-page":"CD007360","article-title":"Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia","volume":"10","author":"Hwang","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_23","first-page":"3","article-title":"Pathophysiology of lower urinary tract symptoms in the aging male population","volume":"7","author":"Lepor","year":"2005","journal-title":"Rev. Urol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ajur.2017.11.005","article-title":"The use of 5-alpha reductase inhibitors in the treatment of benign prostatic hyperplasia","volume":"5","author":"Kim","year":"2018","journal-title":"Asian J. Urol."},{"key":"ref_25","first-page":"412","article-title":"Lower urinary tract symptoms\/benign prostatic hypertrophy and vascular function: Role of the nitric oxide-phosphodiesterase type 5-cyclic guanosine 3\u2019, 5\u2019-monophosphate pathway","volume":"24","author":"Higashi","year":"2017","journal-title":"Int. J. Urol. Off. J. Jpn. Urol. Assoc."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1111\/j.1464-410X.2006.06501.x","article-title":"Pre-clinical evidence for the use of phosphodiesterase-5 inhibitors for treating benign prostatic hyperplasia and lower urinary tract symptoms","volume":"98","author":"Tinel","year":"2006","journal-title":"BJU Int."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/j.1442-2042.2007.01956.x","article-title":"\u03b11-Adrenoceptor subtypes and lower urinary tract symptoms: \u03b11-Adrenoceptor subtypes & LUTS","volume":"15","author":"Schwinn","year":"2008","journal-title":"Int. J. Urol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1002\/pros.20624","article-title":"Change of expression levels of alpha1-adrenoceptor subtypes by administration of alpha1d-adrenoceptor-subtype-selective antagonist naftopidil in benign prostate hyperplasia patients","volume":"67","author":"Kojima","year":"2007","journal-title":"Prostate"},{"key":"ref_29","first-page":"20","article-title":"Medical treatment of benign prostatic hyperplasia","volume":"13","author":"Lepor","year":"2011","journal-title":"Rev. Urol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1002\/nau.20097","article-title":"Evidence for the presence of alpha1 adrenoceptor subtypes in the human ureter","volume":"24","author":"Sigala","year":"2005","journal-title":"Neurourol. Urodyn."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S0022-5347(01)62836-2","article-title":"Alpha1-adrenergic receptor subtypes in human detrusor","volume":"160","author":"Malloy","year":"1998","journal-title":"J. Urol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/S0022-5347(05)65355-4","article-title":"Modulation of bladder alpha1-adrenergic receptor subtype expression by bladder outlet obstruction","volume":"167","author":"Hampel","year":"2002","journal-title":"J. Urol."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Michel, M.C. (2002). Potential role of a1-adrenoceptors in the aetiology of LUTS. Eur. Urol. Suppl., 5\u201313.","DOI":"10.1016\/S1569-9056(02)00118-5"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/j.1476-5381.1996.tb15742.x","article-title":"Quantification and distribution of alpha 1-adrenoceptor subtype mRNAs in human prostate: Comparison of benign hypertrophied tissue and non-hypertrophied tissue","volume":"119","author":"Nasu","year":"1996","journal-title":"Br. J. Pharm."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.juro.2007.10.082","article-title":"Expression of alpha1-adrenoceptor subtype mRNA as a predictor of the efficacy of subtype selective alpha1-adrenoceptor antagonists in the management of benign prostatic hyperplasia","volume":"179","author":"Kojima","year":"2008","journal-title":"J. Urol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"227","DOI":"10.2147\/TCRM.S13883","article-title":"Naftopidil for the treatment of urinary symptoms in patients with benign prostatic hyperplasia","volume":"7","author":"Masumori","year":"2011","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0022-5347(01)61986-4","article-title":"Localization and expression of the alpha1A-1, alpha1B and alpha1D-adrenoceptors in hyperplastic and non-hyperplastic human prostate","volume":"161","author":"Walden","year":"1999","journal-title":"J. Urol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1080\/00325481.2015.1018799","article-title":"Benign prostatic hyperplasia and urinary symptoms: Evaluation and treatment","volume":"127","author":"Mobley","year":"2015","journal-title":"Postgrad. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1474-8673.1996.tb00352.x","article-title":"Drugs for treatment of benign prostatic hyperplasia: Affinity comparison at cloned alpha 1-adrenoceptor subtypes and in human prostate","volume":"16","author":"Michel","year":"1996","journal-title":"J. Auton. Pharm."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1254\/jjp.77.61","article-title":"Vascular alpha1-adrenoceptor subtype selectivity and alpha1-blocker-induced orthostatic hypotension","volume":"77","author":"Take","year":"1998","journal-title":"Jpn. J. Pharm."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1254\/jjp.79.447","article-title":"Naftopidil, a novel alpha1-adrenoceptor antagonist, displays selective inhibition of canine prostatic pressure and high affinity binding to cloned human alpha1-adrenoceptors","volume":"79","author":"Takei","year":"1999","journal-title":"Jpn. J. Pharm."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.ejphar.2016.09.009","article-title":"Pharmaceutical evaluation of naftopidil enantiomers: Rat functional assays in vitro and estrogen\/androgen induced rat benign prostatic hyperplasia model in vivo","volume":"791","author":"Huang","year":"2016","journal-title":"Eur. J. Pharm."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.apsb.2017.04.011","article-title":"Crystal structures, absolute configurations and molecular docking studies of naftopidil enantiomers as \u03b11D-adrenoceptor antagonists","volume":"7","author":"Xu","year":"2017","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e00602","DOI":"10.1002\/prp2.602","article-title":"The affinity and selectivity of \u03b1-adrenoceptor antagonists, antidepressants, and antipsychotics for the human \u03b11A, \u03b11B, and \u03b11D-adrenoceptors","volume":"8","author":"Proudman","year":"2020","journal-title":"Pharm. Res. Perspect."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1177\/1756287212461681","article-title":"The role of naftopidil in the management of benign prostatic hyperplasia","volume":"5","author":"Hara","year":"2013","journal-title":"Ther. Adv. Urol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1111\/j.1464-410X.2006.06030.x","article-title":"Comparison of two alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: A randomized crossover study","volume":"97","author":"Nishino","year":"2006","journal-title":"BJU Int."},{"key":"ref_47","first-page":"1049","article-title":"Kyoto Prefectural University of Medicine Benign Prostatic Hypertrophy Research Group Naftopidil versus tamsulosin hydrochloride for lower urinary tract symptoms associated with benign prostatic hyperplasia with special reference to the storage symptom: A prospective randomized controlled study","volume":"15","author":"Ukimura","year":"2008","journal-title":"Int. J. Urol. Off. J. Jpn. Urol. Assoc."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"74","DOI":"10.4103\/0974-7796.148624","article-title":"A comparison of the efficacy of naftopidil and tamsulosin hydrochloride in medical treatment of benign prostatic enlargement","volume":"7","author":"Perumal","year":"2015","journal-title":"Urol. Ann."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1046\/j.1442-2042.2003.00712.x","article-title":"Usefulness of tamsulosin hydrochloride and naftopidil in patients with urinary disturbances caused by benign prostatic hyperplasia: A comparative, randomized, two-drug crossover study","volume":"10","author":"Ikemoto","year":"2003","journal-title":"Int. J. Urol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"181","DOI":"10.4103\/0974-7796.134254","article-title":"Comparative evaluation of naftopidil and tamsulosin in the treatment of patients with lower urinary tract symptoms with benign prostatic hyperplasia","volume":"6","author":"Griwan","year":"2014","journal-title":"Urol. Ann."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1136\/pgmj.70.823.363","article-title":"Pharmacokinetics of naftopidil, a novel anti-hypertensive drug, in patients with hepatic dysfunction","volume":"70","author":"Farthing","year":"1994","journal-title":"Postgrad. Med. J."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/j.1527-3466.1994.tb00282.x","article-title":"Naftopidil, a novel antihypertensive drug","volume":"12","author":"Himmel","year":"1994","journal-title":"Cardiovasc. Drug Rev."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1111\/jphp.12281","article-title":"Identification of human cytochrome P450 isozymes involved in the metabolism of naftopidil enantiomers in vitro: The metabolism of naftopidil enantiomers","volume":"66","author":"Zhu","year":"2014","journal-title":"J. Pharm. Pharm."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.jpba.2015.04.034","article-title":"Enantiospecific determination of naftopidil by RRLC-MS\/MS reveals stereoselective pharmacokinetics and tissue distributions in rats","volume":"112","author":"Liu","year":"2015","journal-title":"J. Pharm. Biomed. Anal."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1080\/03639045.2019.1656734","article-title":"Development and evaluation of rapidly dissolving buccal films of naftopidil: In vitro and in vivo evaluation","volume":"45","author":"Elagamy","year":"2019","journal-title":"Drug Dev. Ind. Pharm."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1158\/1940-6207.CAPR-10-0189","article-title":"Naftopidil, a selective {alpha}1-adrenoceptor antagonist, suppresses human prostate tumor growth by altering interactions between tumor cells and stroma","volume":"4","author":"Hori","year":"2011","journal-title":"Cancer Prev. Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1158\/1940-6207.CAPR-13-0095","article-title":"Oral naftopidil suppresses human renal-cell carcinoma by inducing G(1) cell-cycle arrest in tumor and vascular endothelial cells","volume":"6","author":"Iwamoto","year":"2013","journal-title":"Cancer Prev. Res."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1159\/000342797","article-title":"Antitumor action of alpha(1)-adrenoceptor blockers on human bladder, prostate and renal cancer cells","volume":"90","author":"Gotoh","year":"2012","journal-title":"Pharmacology"},{"key":"ref_59","first-page":"1563","article-title":"Piperazine-based Alpha-1 AR blocker, Naftopidil, selectively suppresses malignant human bladder cells via induction of apoptosis","volume":"36","author":"Nakagawa","year":"2016","journal-title":"Anticancer Res."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s12154-014-0122-0","article-title":"Identification of a new pharmacological activity of the phenylpiperazine derivative naftopidil: Tubulin-binding drug","volume":"8","author":"Ishii","year":"2015","journal-title":"J. Chem. Biol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/s41419-020-2588-8","article-title":"Bim, Puma and Noxa upregulation by Naftopidil sensitizes ovarian cancer to the BH3-mimetic ABT-737 and the MEK inhibitor Trametinib","volume":"11","author":"Florent","year":"2020","journal-title":"Cell Death Dis."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/ijc.23095","article-title":"Naftopidil, a selective alpha-1 adrenoceptor antagonist, inhibits growth of human prostate cancer cells by G1 cell cycle arrest","volume":"122","author":"Kanda","year":"2008","journal-title":"Int. J. Cancer"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1159\/000368050","article-title":"Naftopidil is useful for the treatment of malignant pleural mesothelioma","volume":"94","author":"Mikami","year":"2014","journal-title":"Pharmacology"},{"key":"ref_64","first-page":"887","article-title":"Naftopidil induces apoptosis in malignant mesothelioma cell lines independently of alpha1-adrenoceptor blocking","volume":"33","author":"Masachika","year":"2013","journal-title":"Anticancer Res."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1111\/iju.12156","article-title":"Reduction of prostate cancer incidence by naftopidil, an alpha1 -adrenoceptor antagonist and transforming growth factor-beta signaling inhibitor","volume":"20","author":"Yamada","year":"2013","journal-title":"Int. J. Urol."},{"key":"ref_66","first-page":"803","article-title":"Autophagy induced by Naftopidil inhibits apoptosis of human gastric cancer cells","volume":"38","author":"Nakamura","year":"2018","journal-title":"Anticancer Res."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1007\/s00432-017-2367-9","article-title":"Combination treatment with naftopidil increases the efficacy of radiotherapy in PC-3 human prostate cancer cells","volume":"143","author":"Iwamoto","year":"2017","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s00432-017-2536-x","article-title":"Additive naftopidil treatment synergizes docetaxel-induced apoptosis in human prostate cancer cells","volume":"144","author":"Ishii","year":"2018","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"500","DOI":"10.3389\/fphys.2018.00500","article-title":"Drug repositioning for effective prostate cancer treatment","volume":"9","author":"Turanli","year":"2018","journal-title":"Front. Physiol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/jid.2013.545","article-title":"A critical evaluation of clinical research study designs","volume":"134","author":"Besen","year":"2014","journal-title":"J. Investig. Dermatol."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Batty, M., Pugh, R., Rathinam, I., Simmonds, J., Walker, E., Forbes, A., Anoopkumar-Dukie, S., McDermott, C.M., Spencer, B., and Christie, D. (2016). The role of alpha1-adrenoceptor antagonists in the treatment of prostate and other cancers. Int. J. Mol. Sci., 17.","DOI":"10.3390\/ijms17081339"},{"key":"ref_72","first-page":"4550","article-title":"Suppression of human prostate cancer cell growth by alpha1-adrenoceptor antagonists doxazosin and terazosin via induction of apoptosis","volume":"60","author":"Kyprianou","year":"2000","journal-title":"Cancer Res."},{"key":"ref_73","first-page":"4550","article-title":"Quinazoline-derived \u03b11-adrenoceptor antagonists induce prostate cancer cell apoptosis via an \u03b11-Adrenoceptor-independent action","volume":"60","author":"Benning","year":"2002","journal-title":"Cancer Res."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1016\/j.juro.2007.06.043","article-title":"Effect of alpha1-adrenoceptor antagonist exposure on prostate cancer incidence: An observational cohort study","volume":"178","author":"Harris","year":"2007","journal-title":"J. Urol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1016\/j.bmcl.2018.03.070","article-title":"Synthesis, biological evaluation and SAR of naftopidil-based arylpiperazine derivatives","volume":"28","author":"Chen","year":"2018","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.1016\/j.ejmech.2011.02.042","article-title":"Design, synthesis and antifungal activities of novel 1,2,4-triazole derivatives","volume":"46","author":"Xu","year":"2011","journal-title":"Eur. J. Med. Chem."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.ejmech.2016.10.043","article-title":"In silico identification, design and synthesis of novel piperazine-based antiviral agents targeting the hepatitis C virus helicase","volume":"125","author":"Bassetto","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"4367","DOI":"10.1016\/j.ejmech.2009.05.029","article-title":"Quantitative structure\u2013activity relationship analysis of aryl alkanol piperazine derivatives with antidepressant activities","volume":"44","author":"Chen","year":"2009","journal-title":"Eur. J. Med. Chem."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.ejmech.2015.02.021","article-title":"Novel 1-(2-aryl-2-adamantyl)piperazine derivatives with antiproliferative activity","volume":"93","author":"Fytas","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"105046","DOI":"10.1016\/j.ejps.2019.105046","article-title":"Design, synthesis, biological evaluation and molecular docking study of arylcarboxamido piperidine and piperazine-based hydroxamates as potential HDAC8 inhibitors with promising anticancer activity","volume":"138","author":"Trivedi","year":"2019","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Chen, H., Xu, B.-B., Sun, T., Zhou, Z., Ya, H.-Y., and Yuan, M. (2017). Synthesis and antitumor activity of novel arylpiperazine derivatives containing the saccharin moiety. Molecules, 22.","DOI":"10.3390\/molecules22111857"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ejmech.2015.04.005","article-title":"Novel naftopidil-related derivatives and their biological effects as alpha1-adrenoceptors antagonists and antiproliferative agents","volume":"96","author":"Huang","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/bcp.13126","article-title":"Microtubule destabilising agents: Far more than just antimitotic anticancer drugs","volume":"83","author":"Bates","year":"2017","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Ho, C.-T., Chang, Y.-J., Yang, L.-X., Wei, P.-L., Liu, T.-Z., and Liu, J.-J. (2015). A novel microtubule-disrupting agent induces endoplasmic reticular stress-mediated cell death in human hepatocellular carcinoma cells. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0136340"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1074\/jbc.M113.499319","article-title":"Novel piperazine-based compounds inhibit microtubule dynamics and sensitize colon cancer cells to tumor necrosis factor-induced apoptosis","volume":"289","author":"Chopra","year":"2014","journal-title":"J. Biol. Chem."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1016\/j.celrep.2016.05.037","article-title":"A Computational drug repositioning approach for targeting oncogenic transcription factors","volume":"15","author":"Gayvert","year":"2016","journal-title":"Cell Rep."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"80","DOI":"10.2174\/1389450114666140106101412","article-title":"Targeting tumor suppressor p53 for cancer therapy: Strategies, challenges and opportunities","volume":"15","author":"Hong","year":"2014","journal-title":"Curr. Drug Targets"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"126744","DOI":"10.1016\/j.bmcl.2019.126744","article-title":"Identification of HUHS190, a human naftopidil metabolite, as a novel anti-bladder cancer drug","volume":"30","author":"Shimizu","year":"2020","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.bmcl.2018.01.068","article-title":"Novel naftopidil derivatives containing methyl phenylacetate and their blocking effects on \u03b11D\/1A-adrenoreceptor subtypes","volume":"28","author":"Huang","year":"2018","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_90","first-page":"1","article-title":"Synthesis and pharmacological evaluation of naftopidil-based arylpiperazine derivatives containing the bromophenol moiety","volume":"PR","author":"Chen","year":"2020","journal-title":"Pharm. Rep."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1111\/cas.12429","article-title":"Newly synthesized anticancer drug HUHS1015 is effective on malignant pleural mesothelioma","volume":"105","author":"Kaku","year":"2014","journal-title":"Cancer Sci."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"21462","DOI":"10.3390\/molecules191221462","article-title":"1-[2-(2-methoxyphenylamino) ethylamino]-3-(naphthalene-1- yloxy) propan-2-ol may be a promising anticancer drug","volume":"19","author":"Nishizaki","year":"2014","journal-title":"Molecules"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1159\/000351747","article-title":"1-[2-(2-methoxyphenylamino) ethylamino]-3-(naphthalene-1-yloxy) propan-2-ol as a potential anticancer drug","volume":"91","author":"Kanno","year":"2013","journal-title":"Pharmacology"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s00280-014-2661-z","article-title":"The newly synthesized anticancer drug HUHS1015 is useful for treatment of human gastric cancer","volume":"75","author":"Kaku","year":"2015","journal-title":"Cancer Chemother Pharm."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"242","DOI":"10.2174\/1871520614666140922122700","article-title":"HUHS1015 induces necroptosis and caspase-independent apoptosis of MKN28 human gastric cancer cells in association with AMID accumulation in the nucleus","volume":"15","author":"Kaku","year":"2015","journal-title":"Anticancer Agents Med. Chem."},{"key":"ref_96","first-page":"39","article-title":"HUHS1015 suppresses colonic cancer growth by inducing necrosis and apoptosis in association with mitochondrial damage","volume":"36","author":"Kaku","year":"2016","journal-title":"Anticancer Res."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"7750","DOI":"10.1021\/jm0580398","article-title":"Structure\u2212activity relationships in 1,4-benzodioxan-related compounds. 8.{2-[2-(4-chlorobenzyloxy) phenoxy] ethyl}-[2-(2,6-dimethoxyphenoxy) ethyl] amine (clopenphendioxan) as a tool to highlight the involvement of \u03b1 1D- and \u03b1 1B- adrenoreceptor subtypes in the regulation of human PC-3 prostate cancer cell apoptosis and proliferation","volume":"48","author":"Quaglia","year":"2005","journal-title":"J. Med. Chem."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.phrs.2015.11.017","article-title":"A selective alpha1D-adrenoreceptor antagonist inhibits human prostate cancer cell proliferation and motility \u201cin vitro\u201d","volume":"103","author":"Colciago","year":"2016","journal-title":"Pharm. Res."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1172\/JCI16293","article-title":"Alpha1-adrenergic receptors activate Ca(2+)-permeable cationic channels in prostate cancer epithelial cells","volume":"111","author":"Thebault","year":"2003","journal-title":"J. Clin. Investig."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Morelli, M.B., Amantini, C., Nabissi, M., Liberati, S., Cardinali, C., Farfariello, V., Tomassoni, D., Quaglia, W., Piergentili, A., and Bonifazi, A. (2014). Cross-talk between alpha1D-adrenoceptors and transient receptor potential vanilloid type 1 triggers prostate cancer cell proliferation. BMC Cancer, 14.","DOI":"10.1186\/1471-2407-14-921"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1185\/03007995.2013.861813","article-title":"Naftopidil for the treatment of benign prostate hyperplasia: A systematic review","volume":"30","author":"Castiglione","year":"2014","journal-title":"Curr. Med. Res. Opin."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/15\/5339\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:52:08Z","timestamp":1760176328000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/15\/5339"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,27]]},"references-count":101,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2020,8]]}},"alternative-id":["ijms21155339"],"URL":"https:\/\/doi.org\/10.3390\/ijms21155339","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,27]]}}}